-
Company Insights
NewAir France – Digital Transformation Strategies
Air France-KLM Digital Transformation Strategies Overview Air France has been focusing on using artificial intelligence, the Internet of Things (IoT), cloud-based mobile applications, big data, and drones to digitally transform its operations. The annual ICT spending of Air France was estimated at $911.8 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Air France-KLM is an international airline group specializing in air passenger transport, cargo transport, and aircraft maintenance....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Non-Small Cell Lung Cancer Drug Details: ORM-5029 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic...
-
Product Insights
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2023’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Seasonal Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Influenza - Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Influenza A Virus, H3N2 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Avian Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Avian Influenza - Drugs In Development, 2023’, provides an overview of the Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Avian Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drugs In Development, 2023’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...